Marcus Schmidt
About
Marcus Schmidt is a scholar working on Oncology, Cancer Research and Pulmonary and Respiratory Medicine.
According to data from OpenAlex, Marcus Schmidt has authored 297 papers receiving a total of 9.0k indexed citations (citations by other indexed papers that have themselves been cited), including 177 papers in Oncology, 102 papers in Cancer Research and 88 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Marcus Schmidt's work include Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (76 papers) and Advanced Breast Cancer Therapies (63 papers). Marcus Schmidt is often cited by papers focused on Breast Cancer Treatment Studies (90 papers), HER2/EGFR in Cancer Research (76 papers) and Advanced Breast Cancer Therapies (63 papers). Marcus Schmidt collaborates with scholars based in Germany, United States and Switzerland. Marcus Schmidt's co-authors include Jan G. Hengstler, Mathias Gehrmann, Igor Bondarenko, Johannes Ettl, Tamás Pintér, Katalin Boér, Dennis J. Slamon, Xin Huang, Richard S. Finn and Ravindranath Patel and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.
In The Last Decade
Marcus Schmidt
284 papers receiving 8.8k citations
Hit Papers
Peers — A (Enhanced Table)
Peers by citation overlap · career bar shows stage (early→late) cites · hero ref
| Name | h | Career | Trend | Papers | Cites | |||||
|---|---|---|---|---|---|---|---|---|---|---|
| Marcus Schmidt Germany | 42 | 5.0k | 2.8k | 2.7k | 2.4k | 852 | 297 | 9.0k | ||
| Carey K. Anders United States | 45 | 5.4k 1.1× | 2.8k 1.0× | 2.6k 1.0× | 2.0k 0.8× | 555 0.7× | 211 | 8.7k | ||
| Linda T. Vahdat United States | 52 | 7.5k 1.5× | 2.1k 0.7× | 2.7k 1.0× | 3.6k 1.5× | 837 1.0× | 236 | 11.5k | ||
| Maura N. Dickler United States | 47 | 6.4k 1.3× | 3.3k 1.2× | 2.8k 1.0× | 3.4k 1.4× | 426 0.5× | 166 | 10.5k | ||
| Rebecca Dent Singapore | 44 | 6.5k 1.3× | 2.4k 0.9× | 4.1k 1.5× | 3.0k 1.2× | 1.1k 1.2× | 186 | 10.2k | ||
| Francesco Cognetti Italy | 46 | 5.0k 1.0× | 2.3k 0.8× | 1.7k 0.6× | 2.4k 1.0× | 454 0.5× | 221 | 8.5k | ||
| Elizabeth Claire Dees United States | 34 | 4.5k 0.9× | 1.4k 0.5× | 2.9k 1.1× | 3.0k 1.2× | 797 0.9× | 127 | 7.9k | ||
| William D. Figg United States | 52 | 3.1k 0.6× | 3.8k 1.3× | 2.4k 0.9× | 4.6k 1.9× | 625 0.7× | 234 | 10.3k | ||
| Ling‐Ming Tseng Taiwan | 43 | 4.9k 1.0× | 1.6k 0.6× | 3.0k 1.1× | 3.6k 1.5× | 521 0.6× | 228 | 8.8k | ||
| Mariano Provencio Spain | 47 | 4.3k 0.9× | 3.3k 1.2× | 2.5k 0.9× | 3.3k 1.4× | 702 0.8× | 468 | 9.1k | ||
| Siqing Fu United States | 51 | 4.1k 0.8× | 2.4k 0.8× | 2.4k 0.9× | 3.8k 1.6× | 954 1.1× | 412 | 9.6k |
Countries citing papers authored by Marcus Schmidt
Since
Specialization
Citations
This map shows the geographic impact of Marcus Schmidt's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Marcus Schmidt with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Marcus Schmidt more than expected).
Fields of papers citing papers by Marcus Schmidt
Since
Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences
This network shows the impact of papers produced by Marcus Schmidt. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Marcus Schmidt. The network helps show where Marcus Schmidt may publish in the future.
Co-authorship network of co-authors of Marcus Schmidt
This figure shows the co-authorship network connecting the top 25 collaborators of Marcus Schmidt. A scholar is included among the top collaborators of Marcus Schmidt based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Marcus Schmidt. Marcus Schmidt is excluded from the visualization to improve readability, since they are connected to all nodes in the network.
All Works
1.
Lohmayer, Regina, Lara Frommherz, Ludger Brühl, et al.. (2025). Overview of the nutrient composition of selected milling products from rye, spelt and wheat in Germany. Journal of Food Composition and Analysis. 140. 107275–107275.
2.
Brühl, Ludger, Ralf Greiner, Alexandra Hüsken, et al.. (2024). Characterization of the nutritional profile of three plant-based drinks. Journal of Food Composition and Analysis. 135. 106553–106553.
3.
Lüftner, Diana, Florian Schuetz, Andreas Schneeweiß, et al.. (2024). Efficacy and safety of everolimus plus exemestane in patients with hormone receptor‐positive, HER ‐2‐negative advanced breast cancer: Results from the open‐label, multicentre, non‐interventional BRAWO study. International Journal of Cancer. 155(1). 128–138.
4.
Schröder, Maria, Valerie Catherine Linz, Slavomir Krajnak, et al.. (2024). Occurrence and Management of Immunotherapy-Associated Adverse Events in Patients with Gynecological Cancers. Cancers. 16(7). 1371–1371.
5.
Decker, Thomas, Nader Hirmas, Kristina Lübbe, et al.. (2023). Anti-hormonal maintenance treatment with the CDK4/6 inhibitor ribociclib after 1st line chemotherapy in hormone receptor positive / HER2 negative metastatic breast cancer: A phase II trial (AMICA). The Breast. 72. 103575–103575.
6.
Almstedt, Katrin, Anne-Sophie Heimes, Franziska Kappenberg, et al.. (2022). Long-term prognostic significance of HER2-low and HER2-zero in node-negative breast cancer. European Journal of Cancer. 173. 10–19.
7.
Krajnak, Slavomir, Thomas Decker, Christian Rosé, et al.. (2021). Phase II study of metronomic treatment with daily oral vinorelbine as first-line chemotherapy in patients with advanced/metastatic HR+/HER2− breast cancer resistant to endocrine therapy: VinoMetro—AGO-B-046. Journal of Cancer Research and Clinical Oncology. 147(11). 3391–3400.
8.
Lebeau, Annette, Carsten Denkert, Hans‐Peter Sinn, Marcus Schmidt, & Achim Wöckel. (2019). Update der S3-Leitlinie Mammakarzinom. Der Pathologe. 40(2). 185–198.
9.
Gerber, B., Marcus Schmidt, Volker Moebus, et al.. (2019). Sorafenib in combination with docetaxel as first-line therapy for HER2-negative metastatic breast cancer: Final results of the randomized, double-blind, placebo-controlled phase II MADONNA study. The Breast. 45. 22–28.
10.
Schad, Arno, C. James Kirkpatrick, Jonathan P. Sleeman, et al.. (2016). Detection of cellular senescence within human invasive breast carcinomas distinguishes different breast tumor subtypes. Oncotarget. 7(46). 74846–74859.
11.
Sahu, Sanjeeb Kumar, Angela Garding, Neha Tiwari, et al.. (2015). JNK ‐dependent gene regulatory circuitry governs mesenchymal fate. The EMBO Journal. 34(16). 2162–2181.
12.
Dubsky, Peter, Jan C. Brase, R. Jakesz, et al.. (2013). The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2− breast cancer patients. British Journal of Cancer. 109(12). 2959–2964.
13.
Minckwitz, Gϋnter von, Kathrin Schwedler, Marcus Schmidt, et al.. (2011). Trastuzumab beyond progression: Overall survival analysis of the GBG 26/BIG 3-05 phase III study in HER2-positive breast cancer. European Journal of Cancer. 47(15). 2273–2281.
14.
Brase, Jan C., Marcus Schmidt, Thomas Fischbach, et al.. (2010). ERBB2 and TOP2A in Breast Cancer: A Comprehensive Analysis of Gene Amplification, RNA Levels, and Protein Expression and Their Influence on Prognosis and Prediction. Clinical Cancer Research. 16(8). 2391–2401.
15.
Cadenas, Cristina, Marcus Schmidt, Mathias Gehrmann, et al.. (2010). Role of thioredoxin reductase 1 and thioredoxin interacting protein in prognosis of breast cancer. Breast Cancer Research. 12(3). R44–R44.
16.
Karn, Thomas, Dirk Metzler, Eugen Ruckhäberle, et al.. (2009). Data driven derivation of cutoffs from a pool of 3,030 Affymetrix arrays to stratify distinct clinical types of breast cancer. Breast Cancer Research and Treatment. 120(3). 567–579.
17.
Schmidt, Marcus, Jan G. Hengstler, Christian von Törne, Heinz Koelbl, & Mathias Gehrmann. (2009). Coordinates in the Universe of Node-Negative Breast Cancer Revisited. Cancer Research. 69(7). 2695–2698.
18.
Schmidt, Marcus, Dirk Hasenclever, Daniel Boehm, et al.. (2008). Prognostic Effect of Epithelial Cell Adhesion Molecule Overexpression in Untreated Node-Negative Breast Cancer. Clinical Cancer Research. 14(18). 5849–5855.
19.
Schmidt, Marcus, Daniel Böhm, Christian von Törne, et al.. (2008). The Humoral Immune System Has a Key Prognostic Impact in Node-Negative Breast Cancer. Cancer Research. 68(13). 5405–5413.
20.
Schmidt, Marcus, Berno Tanner, Henryk Pilch, et al.. (2005). Long-term prognostic significance of HER-2/neu in untreated node-negative breast cancer depends on the method of testing. Breast Cancer Research. 7(2). R256–66.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.
Explore authors with similar magnitude of impact
Breakdown of academic impact, for papers by Carey K. Anders Breakdown of academic impact, for papers by Linda T. Vahdat Breakdown of academic impact, for papers by Maura N. Dickler Breakdown of academic impact, for papers by Rebecca Dent Breakdown of academic impact, for papers by Francesco Cognetti Breakdown of academic impact, for papers by Elizabeth Claire Dees Breakdown of academic impact, for papers by William D. Figg Breakdown of academic impact, for papers by Ling‐Ming Tseng Breakdown of academic impact, for papers by Mariano Provencio Breakdown of academic impact, for papers by Siqing Fu